IP Library Granted Patent US 6,936,414
Granted Patent B2
US 6,936,414 · App. 09/470,944 · Granted Aug 30, 2005

Nucleic acid isolation method and kit

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,936,414
App. No.
09/470,944
Granted
Aug 30, 2005
Kind
B2
Abstract

Provided herein is a method for separating nucleic acid from a test sample comprising the steps of contacting a test sample with a metal oxide support material and a binding buffer to form nucleic acid/metal oxide support material complexes, separating the complexes from the test sample; and eluting the nucleic acid from the metal oxide support material.

Claims (22)

1. A method for separating nucleic acid from a test sample comprising:

a) contacting a test sample with a metal oxide support material and a binding buffer such that the nucleic acid bonds with the metal oxide support material to form complexes without prior purification or precipitation of the nucleic acid, wherein the binding buffer comprises

a chaotropic agent and

a detergent

and wherein the binding buffer contains no or a low concentration of organic solvent such that the flashpoint of the binding buffer is greater than 130 degrees Fahrenheit;

b) separating the complexes from the test sample; and

c) eluting the nucleic acid from the metal oxide support material, thereby separating the nucleic acid from the test sample,

wherein step a) allows the nucleic acids to be directly employed in an amplification reaction without exchanging an elution buffer and wherein the test sample is selected from the group consisting of blood, ocular lens fluid, cerebral fluid, milk, ascites fluid, synovial fluid, peritoneal fluid, amniotic fluid, tissue, fermentation broth, and cell culture.

2. The method of claim 1 wherein the binding buffer further comprises a reducing agent.

3. The method of claim 1 further comprising a wash step after separating the complexes from the test sample and before eluting the nucleic acid from the metal oxide support material.

4. The method of claim 1 wherein eluting the nucleic acid from the metal oxide support material comprises contacting the complexes with a reagent selected from the group consisting of water and a phosphate containing buffer.

5. The method of claim 4 further comprising the step of detecting the nucleic acid after the eluting the nucleic acid from the metal oxide support material.

6. The method of claim 5 further comprising the step of amplifying the nucleic acid after eluting the nucleic acid from the metal oxide support material and before detecting the nucleic acid.

7. The method of claim 5 wherein the nucleic acid is separated from a test sample comprising more than one source of nucleic acid.

8. The method of claim 7 wherein the nucleic acid separated from the test sample comprises RNA and DNA.

9. The method of claim 6 wherein the step of amplifying the nucleic acid is performed without removal of the elution buffer.

10. The method of claim 1 wherein eluting the nucleic acid from the metal oxide support material comprises contacting the complexes with an elution buffer having a pH of between 6 and 10.

11. The method of claim 1 wherein eluting the nucleic acid from the metal oxide support material comprises contacting the complexes with an elution buffer having a pH of between 7 and 9.

12. The method of claim 1 wherein eluting the nucleic acid from the metal oxide support material comprises contacting the complexes with an elution buffer comprising a sodium phosphate or organophosphate compound such that the phosphate concentration in the elution buffer is from 10 mM to 300 mM.

13. The method of claim 1 wherein eluting the nucleic acid from the metal oxide support material comprises contacting the complexes with an elution buffer comprising a sodium phosphate or organophosphate compound such that the phosphate concentration in the elution buffer is from 10 mM to 100 mM.

14. The method of claim 1 wherein the nucleic acid is HIV nucleic acid from plasma.

15. The method of claim 1 wherein the nucleic acid is HBV nucleic acid from plasma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2015
From: ABBOTT LABORATORIES
To: ABBOTT MOLECULAR INC.
Reel/Frame 034924/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2000
From: GUNDLING, GERARD
To: ABBOTT LABORATORIES
Reel/Frame 010759/0878 →
Continuity (1)
Related Publication 20020068821A1 · Jun 6, 2002